Shares of AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report) hit a new 52-week high during trading on Tuesday . The company traded as high as $14.93 and last traded at $9.90, with a volume of 41869 shares trading hands. The stock had previously closed at $9.50.
AIM ImmunoTech Price Performance
The firm has a market capitalization of $755.43 million, a price-to-earnings ratio of -22.86 and a beta of 0.76. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average price of $0.09 and a two-hundred day moving average price of $0.14.
AIM ImmunoTech Company Profile
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Read More
- Five stocks we like better than AIM ImmunoTech
- What Are Dividend Contenders? Investing in Dividend Contenders
- Applied Digital: Now the High-Stakes Race to Build Begins
- How to Buy Gold Stock and Invest in Gold
- Zscaler Upgraded: Wall Street Forecasts 26% More Upside
- What is the Euro STOXX 50 Index?
- The Bottom Is in for Powerfleet: An Intelligent Time to Buy
Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.
